Labcorp Holdings Inc. (LH)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $30.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Labcorp Holdings Inc. (LH) Stock Forecast
Analysts expect Labcorp Holdings (LH) to earn $18.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $14.83B. Of 17 analysts, 12 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 12 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.18, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 11.8% |
| Buy | 10 | 58.8% |
| Hold | 5 | 29.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 6.0% and revenue estimates rise 5.4%.
- Fiscal year ending Dec 31, 2026
- $18.49
- EPS consensus, revenue $14.83B
- Fiscal year ending Dec 31, 2027
- $19.60
- EPS consensus, revenue $15.63B
- Next report
- Feb 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $18.49 | $18.24 to $18.62 | 18 | $14.83B | $14.73B to $14.87B | 16 |
| Dec 31, 2027 | $19.60 | $17.24 to $20.65 | 18 | $15.63B | $15.32B to $15.94B | 16 |
Quarterly Estimates
The EPS consensus falls from $4.65 for the quarter ending Dec 31, 2026 to $4.54 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.65 | $4.25 to $4.84 | 18 | $3.86B | $3.61B to $3.98B | 17 |
| Mar 31, 2027 | $4.54 | $4.26 to $4.79 | 10 | $3.73B | $3.69B to $3.76B | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 21 upward and 15 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 12 | 3 |
| Fiscal year ending Dec 31, 2027 | 7 | 9 |
| Quarter ending Mar 31, 2027 | 2 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.6% from $18.38.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $18.49 | $18.42 | $18.36 | $18.36 | $18.38 | +0.6% |
| Fiscal year ending Dec 31, 2027 | $19.60 | $19.64 | $19.81 | $19.82 | $19.76 | -0.8% |
| Quarter ending Mar 31, 2027 | $4.54 | $4.59 | $4.61 | $4.61 | $4.61 | -1.5% |
Frequently Asked Questions About LH
What is the LH stock forecast?
Consensus analyst estimates put Labcorp Holdings's EPS at $18.49 for the fiscal year ending Dec 31, 2026, on revenue of $14.83B. The consensus rating from 17 analysts is Buy.
How do analysts rate LH stock?
Of 17 analysts covering Labcorp Holdings, 2 rate it Strong Buy, 10 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $18.49, with estimates from $18.24 to $18.62 from 18 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $19.60, with estimates from $17.24 to $20.65 from 18 analysts.
What revenue do analysts expect from Labcorp Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $14.83B, with estimates from $14.73B to $14.87B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $15.63B, with estimates from $15.32B to $15.94B.
How many analysts cover LH?
17 analysts rate Labcorp Holdings stock, and 18 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts